Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Opioid Dependence (Mar 2019)

Posted by Matt Breese on Mar 29, 2019

Find me on:

According to our recent payer coverage analysis for opioid dependence treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for opioid dependence treatments shows that under the pharmacy benefit, more than 42% of the lives under commercial formularies are covered without utilization management restrictions. 

MMIT-Reality Check-Opioid Dependence_1Q2019Data snapshot as of Q1 2019

Trends: To combat the opioid crisis, CMS in June 2018 guidance included an Information Bulletin providing states with considerations when designing approaches to covering critical treatment services for Medicaid-eligible infants with Neonatal Abstinence Syndrome, a post-natal opioid withdrawal syndrome that causes lengthy and costly hospital stays. Via AIS Health.

To read the full Reality Check on Opioid Dependence treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing